Barry Simon, M.D.
Dr. Barry Simon is a healthcare executive with more than 30 years of experience spanning the public and private sectors. He currently serves as President and CAO at Nantkwest (NASDAQ: NK), an Immuno-therapeutics company, and from 2007-2015 served as its President and CEO. Since 2017, Dr. Simon has been serving as a Director for Viracta Therapeutics, a privately held oncology therapeutics company, and since 2015 has also been serving as President and CEO and Director for Brink Biologics, Inc., a privately held diagnostics and laboratory services provider specializing in monoclonal antibody and vaccine testing. Dr. Simon previously held various vice president, senior level executive and advisory positions at Roche Labs, F. Hoffmann-La Roche (VTX: ROG), Connetics Corp. (NASDAQ: CNCT), Immunomedics (NASDAQ: IMMU), Immusol Inc., NorthSound Capital, LLC, and HealthPro BioVentures. He has broad experience with product and portfolio divestitures and acquisitions, strategic licensing and joint ventures in addition to commercial product launches, IND and BLA regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He trained clinically in infectious diseases, anesthesiology and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.« Go Back